Gene variant boosts ulcer susceptibility in NSAID users
A single nucleotide polymorphism in the cytochrome P450 2C gene cluster influences the risk for peptic ulcer disease in people taking non-steroidal anti-inflammatory drugs, a study reveals.
View ArticleBD receives FDA approval for second prefilled injectable drug
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the...
View ArticleGenetic loci associated with H pylori bacteria are linked to stomach cancer
Two genome-wide association studies and a subsequent meta-analysis have found that certain genetic variations are associated with susceptibility to Helicobacter pylori, a bacteria that is a major cause...
View ArticleColumbia University, Chinese Center for Disease Control to open joint...
The Center for Infection and Immunity at Columbia University's Mailman School of Public Health and the National Institute for Viral Disease Control and Prevention within the Chinese Center for Disease...
View ArticleStudy shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs
A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event is taking...
View ArticleDiclegis delayed-release tablets for NVP treatment now eligible for Medicaid...
Duchesnay USA today announced that Diclegis (doxylamine succinate 10mg, pyridoxine hydrochloride 10mg) delayed-release tablets for the treatment of nausea and vomiting of pregnancy, more commonly known...
View ArticleGIQuIC expands endoscopic quality registry to include upper GI endoscopy
The GI Quality Improvement Consortium announces the expansion of its endoscopic quality registry to include upper GI endoscopy and related quality measures. GIQuIC, a quality benchmarking registry...
View ArticleNew animal model may help study immune responses to H. pylori infection
Researchers at the Virginia Bioinformatics Institute at Virginia Tech have developed a new large animal model to study how the immune system interacts with the stomach bacterium Helicobacter pylori,...
View ArticleCumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.
View ArticleNew classification system to manage emergency surgery described in special...
Researchers in Finland have implemented a classification system for emergency operations that allows for a fair and efficient way to manage a large volume of such surgery.
View ArticleActavis reports positive results from ceftazidime-avibactam Phase III studies...
Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment...
View ArticleGlobal Peptic Ulcer Drugs market expected to grow at CAGR of 2.9% over 2013-2018
Research and Markets has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" report to their offering.
View ArticleNow, women experiencing morning sickness can benefit from Diclegis drug
Up to 85 percent of pregnant women are affected by nausea and vomiting of pregnancy (NVP), more commonly known as morning sickness.
View ArticleGenetic loci associated with H pylori bacteria are linked to stomach cancer
Two genome-wide association studies and a subsequent meta-analysis have found that certain genetic variations are associated with susceptibility to Helicobacter pylori, a bacteria that is a major cause...
View ArticleFDA approves RYTARY for Parkinson's disease treatment
Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of...
View ArticleEgalet announces net revenues of $1.9 million for 2014
Egalet Corporation today reported financial results for the year ended December 31, 2014.
View ArticleLoyola's Neil Gupta recommends patients to ask four questions when planning a...
"Most people focus on the dislike of the preparation, the need to arrange transportation and the fear of being anesthetized during the procedure and then potentially getting a cancer diagnosis," says...
View ArticleEgalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the...
View ArticleNew data support use of Exalenz Bioscience's BreathID test for diagnosing H....
Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced new published data...
View ArticlePositive CHMP opinion recommends RELISTOR for treatment of opioid-induced...
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a...
View Article
